

Table S1: NMR Data of compound **1** (CD₃OD, 600 and 150 MHz for ¹H and ¹³C, respectively)

Position	δ _C	δ _H (<i>J</i> in Hz)	COSY Characteristic correlations	HMBC Characteristic correlations
Aglycone (myricetin)				
2	158.0			
3	135.3			
4	178.9			
5	163.1			
6	99.7	6.15 (d, 2.1)		
7	165.7			
8	94.4	6.32 (d, 2.1)		
9	158.2			
10	105.9			
1'	122.0			
2'	109.8	7.27 (s)		
3'	146.4			
4'	137.9			
5'	146.4			
6'	109.8	7.27 (s)		
3-O-galactopyranoside moiety				
1''	101.4	5.78 (d, 8)	H-2''	3, 5'', 3''
2''	74.6	5.45 (dd, 9.9, 8)	H-1'', H-3''	3'', 1'', 7''
3''	73.5	3.84 (dd, 9.9, 3.4)	H-2'', H4''	
4''	70.6	3.96 (dd, 3.3, 1.3)	H-3'', H-5''	
5''	77.5	3.61 (t, 6.3)	H-4'', H-6''	
6'' (2H)	62.1	3.70 (m)	H-5''	
2''-O-galloyl moiety				
1'''	121.7	-		
2'''	110.7	7.14 (s)		
3'''	146.3	-		
4'''	139.9	-		
5'''	146.3	-		
6'''	110.7	7.14 (s)		
7''' (C=O)	168.4	-		

Table S2: NMR Data of compound **2** (CD₃OD, 600 and 150 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (J in Hz)	COSY Characteristic correlations
Aglycone (myricetin)			
2	158.6		
3	135.7		
4	179.4		
5	163.3		
6	99.9	6.19 (d, 2.1)	
7	166.0		
8	94.7	6.36 (d, 2.1)	
9	159.5		
10	105.9		
1'	121.8		
2'	110.4	7.07 (s)	
3'	146.5		
4'	138.0		
5'	146.5		
6'	110.4	7.07 (s)	
3-O-rhamnopyranosyl moiety			
1''	100.5	5.51 (d, 1.5)	H-2''
2''	73.5	5.63 (dd, 3.3, 1.7)	H-1'', H-3''
3''	70.8	4.04 (dd, 9.5, 3.3)	H-2''', H-4'''
4''	73.9	3.47 (t, 9.7)	H-3''', H-5'''
5''	72.3	3.49 (dd, 9.7, 6.3)	H4''', H-6'''
6''	17.8	1.04 (d, 6)	H-5'''
2''-O-galloyl moiety			
1'''	121.3	-	
2'''	109.6	6.98 (s)	
3'''	146.9	-	
4'''	140.0	-	
5'''	146.9	-	
6'''	109.6	6.98 (s)	
7''' (C=O)	167.5	-	

Table S3: NMR Data of compound **3** (CD₃OD, 400 and 100 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (J in Hz)	COSY Characteristic correlations	HMBC Characteristic correlations
Aglycone (myricetin)				
2	157.1			
3	135.0			
4	178.2			
5	161.8			
6	98.4	6.20 (d, 1.6)		
7	164.5			
8	93.3	6.37 (d, 1.6)		
9	158.0			
10	104.5			
1'	120.5			
2'	108.2	6.99 (s)		
3'	145.5			
4'	136.5			
5'	145.5			
6'	108.2	6.99 (s)		
3-O-rhamnopyranosyl moiety				
1''	102.3	5.28 (d, 1.4)	H-2''	3, 5'', 3''
2''	70.9	4.48 (dd, 3.1, 1.4)	H-1'', H-3''	
3''	69.5	5.24 (dd, 9.1, 3.1)	H-2'', H-4''	5'', 7''
4''	73.9	3.69 (m, overlaped)	H-3'', H-5''	
5''	68.6	3.69 (m, overlaped)	H4'', H-6''	
6''	16.3	1.0 (d, 5.6)	H-5''	
3''-O-galloyl moiety				
1'''	120.2	-		
2'''	109.1	7.17 (s)		
3'''	145.0	-		
4'''	138.5	-		
5'''	145.0	-		
6'''	109.1	7.17 (s)		
7''' (C=O)	167.0	-		

Table S4: NMR Data of compound **4** (CD₃OD, 400 and 100 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (<i>J</i> in Hz)
Gallic acid		
1	122.3	-
2	110.3	6.93 (s)
3	146.4	-
4	139.5	-
5	146.4	-
6	110.3	6.93 (s)
7	170.6	-

Table S5: NMR Data of compound **5** (CD₃OD, 400 and 100 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (J in Hz)
Aglycone (myricetin)		
2	157.0	
3	134.6	
4	177.9	
5	161.1	
6	98.6	6.22 (d, 2)
7	164.2	
8	93.3	6.42 (d, 2)
9	157.5	
10	105.9	
1'	121.7	
2'	108.5	7.41 (s)
3'	145.0	
4'	137.0	
5'	145.0	
6'	108.5	7.41 (s)
3-O-galactopyranoside moiety		
1''	104.2	5.19 (d, 7.8)
2''	71.8	3.90 (dd, 9.5, 7.8)
3''	75.8	3.70 (dd, 9.5, 3.4)
4''	68.6	3.65 (dd, 3.0, 1.5)
5''	73.7	3.61 (t, 6.3)
6''a	60.5	3.86 (dd, 10.3, 6.0)
6''b		3.52 (dd, 10.3, 6.7)

Table S6: NMR Data of compound **6** (DMSO-d₆, 600 and 150 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (J in Hz)
Aglycone (apigenin)		
2	165.1	-
3	103.8	6.59 (s)
4	182.9	-
5	162.4	-
6	100.1	6.12 (d, 2.1)
7	165.2	-
8	95.3	6.41 (d, 2.1)
9	158.5	-
10	104.8	-
1'	122.4	-
2'	129.6	7.79 (d, 8.9)
3'	117.2	6.86 (d, 8.9)
4'	162.1	-
5'	117.2	6.86 (d, 8.9)
6'	129.6	7.79 (d, 8.9)

Table S7: NMR Data of compound **7** (CD₃OD, 400 and 100 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (<i>J</i> in Hz)
Aglycone (myricetin)		
2	146.6	
3	135.9	
4	175.9	
5	161.1	
6	97.8	6.20 (d, 2)
7	164.2	
8	92.9	6.40 (d, 2)
9	156.8	
10	103.1	
1'	121.7	
2'	107.1	7.36 (s)
3'	145.3	
4'	135.5	
5'	145.3	
6'	107.1	7.36 (s)

Table S8: NMR Data of compound **8** (CD₃OD, 400 and 100 MHz for ¹H and ¹³C, respectively)

Position	δ_C	δ_H (<i>J</i> in Hz)
Ethyl gallate		
1	120.4	-
2	108.9	7.07 (s)
3	145.1	-
4	138.3	-
5	145.1	-
6	108.9	7.07 (s)
7	167.6	-
8	60.3	4.28 (q, 6.68)
9	13.2	1.35 (t, 6.44)




Fig. S1. $^1\text{H-NMR}$ spectrum (600 MHz, CD_3OD) of compound **1**




Fig. S2. $^{13}\text{C-NMR}$ spectrum (150 MHz, CD_3OD) of compound **1**




Fig. S3. COSY spectrum of compound **1**




Fig. S4. HSQC spectrum of compound **1**




Fig. S5. HMBC spectrum of compound 1




Fig. S6. ESI-MS m/z of compound **1**





Fig. S7. ^1H -NMR spectrum (600 MHz, CD_3OD) of compound **2**




Fig. S8. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of compound 2




Fig. S9. COSY spectrum of compound **2**




Fig. S10. ESI-MS m/z of compound 2





Fig. S11. ¹H-NMR spectrum (400 MHz, CD₃OD) of compound **3**




Fig. S12. ^{13}C -NMR spectrum (100 MHz, CD_3OD) of compound **3**




Fig. S13. COSY spectrum of compound **3**




Fig. S14. HMBC spectrum of compound **3**




Fig. S15. ¹H-NMR spectrum (400 MHz, CD₃OD) of compound **4**




Fig. S16. ¹³C-NMR spectrum (100 MHz, CD₃OD) of compound **4**




Fig. S17. $^1\text{H-NMR}$ spectrum (400 MHz, CD_3OD) of compound **5**




Fig. S18. $^{13}\text{C-NMR}$ spectrum (100 MHz, CD_3OD) of compound **5**




Fig. S19. ^1H -NMR spectrum (600 MHz, DMSO- d_6) of compound **6**




Fig. S20. ^{13}C -NMR spectrum (150 MHz, DMSO- d_6) of compound **6**




Fig. S21. ^1H -NMR spectrum (400 MHz, CD_3OD) of compound **7**




Fig. S22. ^{13}C -NMR spectrum (100 MHz, CD_3OD) of compound **7**




Fig. S23. ^1H -NMR spectrum (400 MHz, CD_3OD) of compound **8**




Fig. S24. ^{13}C -NMR spectrum (100 MHz, CD_3OD) of compound **8**





Fig. S25. 2D and 3D ligand interactions of compound 4 with main protease receptor





Fig. S26. 2D and 3D ligand interactions of compound **5** with main protease receptor





Fig. S27. 2D and 3D ligand interactions of compound 6 with main protease receptor





Fig. S28. 2D and 3D ligand interactions of compound **7** with main protease receptor





Fig. S29. 2D and 3D ligand interactions of compound **8** with main protease receptor





Fig. S30. 2D and 3D ligand interactions of compound **Remdesivir** with main protease receptor





Fig. 31. 2D and 3D ligand interactions of compound **3** with spike glycoprotein





Fig. S32. 2D and 3D ligand interactions of compound **4** with spike glycoprotein





Fig. S33. 2D and 3D ligand interactions of compound **5** with spike glycoprotein





Fig. S34. 2D and 3D ligand interactions of compound 6 with spike glycoprotein





Fig. S35. 2D and 3D ligand interactions of compound 7 with spike glycoprotein





Fig. S36. 2D and 3D ligand interactions of compound **8** with spike glycoprotein





Fig. S37. 2D and 3D ligand interactions of compound **remdesivir** with spike glycoprotein



Fig. S38. Photo of the aerial parts of *Limonium tubiflorum* (Delile) Kuntze var *tubiflorum*